Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions

NCT01583816 is registered in ClinicalTrials.gov with Spirig Pharma Ltd. as lead sponsor.

NCT NCT01583816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01583816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions
Lead sponsor
Spirig Pharma Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
June 30, 2014
Enrollment
218 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis